Petmed Express Inc (NASDAQ:PETS) has earned an average recommendation of “Sell” from the six research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $32.00.
PETS has been the subject of several research analyst reports. BidaskClub raised shares of Petmed Express from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 22nd. TheStreet cut shares of Petmed Express from a “b” rating to a “c+” rating in a research note on Thursday, November 29th. Finally, ValuEngine raised shares of Petmed Express from a “strong sell” rating to a “sell” rating in a research note on Friday, October 26th.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado lifted its position in Petmed Express by 265.5% during the third quarter. Public Employees Retirement Association of Colorado now owns 3,922 shares of the company’s stock valued at $129,000 after purchasing an additional 2,849 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Petmed Express during the second quarter valued at $154,000. First Hawaiian Bank bought a new position in Petmed Express during the fourth quarter valued at $193,000. OppenheimerFunds Inc. bought a new position in Petmed Express during the second quarter valued at $205,000. Finally, Schroder Investment Management Group bought a new position in Petmed Express during the second quarter valued at $214,000. 95.04% of the stock is owned by institutional investors.
Petmed Express (NASDAQ:PETS) last announced its quarterly earnings data on Monday, October 22nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.02. The firm had revenue of $71.40 million during the quarter, compared to analysts’ expectations of $71.93 million. Petmed Express had a net margin of 14.88% and a return on equity of 35.53%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share.
About Petmed Express
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
See Also: Why is insider trading harmful?
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.